Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry alerts policymakers to devices as population ages:

This article was originally published in Clinica

Executive Summary

The European medical device industry association, Eucomed, has issued a press release drawing attention to the growing importance of medical devices in the years ahead as the population ages. According to that release, issued on the International Day of Older Persons on October 1, some 10% of the population is now 60 years of over - by 2050, this figure will reach 20% and by 2150, 33%. There are striking differences between regions, it says, with 20% of Europeans but just 5% of Africans 60 or over. During the first half of the 21st century, the proportion of over 60s in Europe will reach one in four in some countries, and even one in two in others. The potential for medical devices to help eliminate or greatly reduce the disabilities related to ageing and lead to more active lives is clear. Eucomed calls for equitable access to the simple devices - such as hearing aids and incontinence pads - as well as to the more high-tech devices that can dramatically improve the quality of life of older people with a life-threatening condition - such as heart valves or implantable pacemakers.

You may also be interested in...



Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT063794

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel